Background and Objectives: Photodynamic therapy (PDT) with porfimer sodium, FDA approved to treat premalignant lesions in Barrett's esophagus, causes photosensitivity for 6-8 weeks. HPPH (2-[1-hexyloxyethyl]-2devinyl pyropheophorbide-a) shows minimal photosensitization of short duration and promisin
Photodynamic therapy using 5-aminolaevulinic acid for oesophageal adenocarcinoma associated with Barrett’s metaplasia
✍ Scribed by W.C Tan; C Fulljames; N Stone; A.J Dix; N Shepherd; D.J.H Roberts; S.B Brown; N Krasner; H Barr
- Publisher
- Elsevier Science
- Year
- 1999
- Tongue
- English
- Weight
- 133 KB
- Volume
- 53
- Category
- Article
- ISSN
- 1011-1344
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Photodynamic therapy (PDT) using topical 5‐aminolaevulinic acid (ALA) has been used to treat histologically confirmed cervical intraepithelial neoplasia (CIN‐I and ‐I/II) in a randomised, double‐blind, placebo‐controlled protocol. Fluorescence microscopy revealed that topical applicatio
## Abstract ## Background and Objectives Surgical excision of primary nasopharyngeal papillary adenocarcinoma is sometimes incomplete with remaining microscopic disease. Post‐operative radiotherapy only has limited efficacy but may cause many complications. ## Study Design/Materials and Methods